The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is driven by favorable government policies such as the U.S. Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence market growth.
Comments
Content
The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is driven by favorable government policies such as the U.S. Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence market growth.